Table 3.
Univariate log-rank and multivariate analyses for disease-specific and metastasis-free survivals in upper urinary tract urothelial carcinoma.
| Parameter | Category | Case No. | Disease-specific survival | Metastasis-free survival | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | |||||||||
| No. of event | p-value | RR | 95% CI | p-value | No. of event | p-value | RR | 95% CI | p-value | |||
| Gender | Male | 158 | 28 | 0.8286 | – | – | – | 32 | 0.7904 | – | – | – |
| Female | 182 | 33 | – | – | – | 38 | – | – | – | |||
| Age (years) | <65 | 138 | 26 | 0.9943 | – | – | – | 30 | 0.8470 | – | – | – |
| ≥65 | 202 | 35 | – | – | – | 40 | – | – | – | |||
| Tumor side | Right | 177 | 34 | 0.7366 | – | – | – | 38 | 0.3074 | – | – | – |
| Left | 154 | 26 | – | – | – | 32 | – | – | – | |||
| Bilateral | 9 | 1 | – | – | – | 0 | – | – | – | |||
| Tumor location | Renal pelvis | 141 | 24 | 0.0079* | 1 | – | 0.476 | 31 | 0.0659 | – | – | – |
| Ureter | 150 | 22 | 0.763 | 0.411–1.417 | 25 | – | – | – | ||||
| Renal pelvis and ureter | 49 | 15 | 1.675 | 0.462–6.067 | 14 | – | – | – | ||||
| Multifocality | Single | 273 | 48 | 0.0026* | 1 | – | 0.340 | 52 | 0.0127* | 1 | – | 0.001* |
| Multifocal | 62 | 18 | 1.833 | 0.528–6.372 | 18 | 2.678 | 1.525–4.703 | |||||
| Primary tumor (T) | Ta | 89 | 2 | <0.0001* | 1 | – | 0.177 | 4 | <0.0001* | 1 | – | 0.118 |
| T1 | 92 | 9 | 3.575 | 0.763–16.756 | 15 | 3.178 | 1.034–9.772 | |||||
| T2–T4 | 159 | 50 | 4.226 | 0.926–19.284 | 51 | 2.251 | 0.704–7.192 | |||||
| Nodal metastasis | Negative (N0) | 312 | 42 | <0.0001* | 1 | – | <0.001* | 55 | <0.0001* | 1 | – | 0.001* |
| Positive (N1–N2) | 28 | 19 | 5.421 | 2.932–10.022 | 15 | 2.893 | 1.555–5.385 | |||||
| Histological grade | Low grade | 56 | 4 | 0.0215* | 1 | – | 0.045* | 3 | 0.0027* | 1 | – | 0.158 |
| High grade | 284 | 57 | 2.765 | 1.021–7.488 | 67 | 1.781 | 0.799–3.967 | |||||
| Vascular invasion | Absent | 234 | 24 | <0.0001* | 1 | – | 0.204 | 26 | <0.0001* | 1 | – | 0.002* |
| Present | 106 | 37 | 1.478 | 0.809–2.700 | 44 | 2.539 | 1.403–4.595 | |||||
| Perineural invasion | Absent | 321 | 50 | <0.0001* | 1 | – | <0.001* | 61 | <0.0001* | 1 | – | 0.027* |
| Present | 19 | 11 | 3.970 | 1.907–8.265 | 9 | 2.310 | 1.102–4.842 | |||||
| Mitotic rate (per 10 high-power fields) | <10 | 173 | 27 | 0.167 | – | – | 30 | 0.0823 | – | - | ||
| FBLN2 expression | ≥10 | 167 | 34 | – | – | 40 | – | – | ||||
| Low | 170 | 11 | <0.0001* | 1 | – | 0.012* | 14 | <0.0001* | 1 | – | 0.001* | |
| High | 170 | 50 | 2.561 | 1.219–4.968 | 56 | 2.837 | 1.504–5.349 | |||||
*
Statistically significant.